| NCT07209332 | Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | PHASE2 | 2025-11 | 2029-03 | 2029-03 |
| NCT06842186 | A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity | RECRUITING | PHASE1 | 2025-01-31 | 2026-10 | 2026-10 |
| NCT06405633 | A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD | RECRUITING | PHASE1, PHASE2 | 2024-07-19 | 2026-09 | 2026-09 |
| NCT06186492 | A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) | COMPLETED | PHASE1 | 2023-11-14 | 2025-02-13 | 2025-02-13 |
| NCT05683860 | Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) | TERMINATED | PHASE1, PHASE2 | 2022-12-14 | 2023-06-30 | 2023-06-30 |
| NCT04906460 | Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) | RECRUITING | PHASE1, PHASE2 | 2021-09-28 | 2027-04-24 | 2026-06-27 |
| NCT05032196 | Study of WVE-003 in Patients With Huntington's Disease | COMPLETED | PHASE1, PHASE2 | 2021-09-06 | 2024-05-24 | 2024-05-24 |
| NCT04931862 | Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) | TERMINATED | PHASE1, PHASE2 | 2021-06-28 | 2023-06-27 | 2023-06-27 |
| NCT04617847 | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease | TERMINATED | PHASE1, PHASE2 | 2020-04-13 | 2021-05-03 | 2021-05-03 |
| NCT04617860 | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease | TERMINATED | PHASE1, PHASE2 | 2019-09-24 | 2021-04-29 | 2021-04-29 |
| NCT03907072 | Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy | TERMINATED | PHASE2, PHASE3 | 2019-09-04 | 2020-01-09 | 2019-12-16 |
| NCT03508947 | Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy | COMPLETED | PHASE1 | 2018-01-24 | 2019-03-06 | 2019-03-06 |
| NCT03225833 | Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease | TERMINATED | PHASE1, PHASE2 | 2017-07-17 | 2021-05-11 | 2021-05-11 |
| NCT03225846 | Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease | TERMINATED | PHASE1, PHASE2 | 2017-07-17 | 2021-05-10 | 2021-05-10 |